This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mannoor, M. Articles by Sato, Y Search for Related Content PubMed PubMed Citation Articles by Mannoor, M. Articles by Sato, Y Social Bookmarking                         What's this?

Honeybee royal jelly inhibits autoimmunity in SLE-prone NZB x NZW F1 mice

Department of Social and Environmental Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan Kaiissar{at}med.u-ryukyu.ac.jp

I Shimabukuro

Department of Social and Environmental Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan

M Tsukamotoa

Department of Social and Environmental Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan; Department of Apiculture Research, Japan Royal Jelly (JRJ) Co. Ltd, Tokyo, Japan

H Watanabe

Division of Cellular and Molecular Immunology, Center of Molecular Biosciences, University of the Ryukyus, Okinawa, Japan

K Yamaguchi

Department of Apiculture Research, Japan Royal Jelly (JRJ) Co. Ltd, Tokyo, Japan; Apis Cerana Research Institute, Yunnan Agricultural University, Yunnan, China

Y Sato

Department of Social and Environmental Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan

Royal jelly (RJ) is a gelatinous secretion from young nurse worker bees (Apis mellifera), which serves as the sole food for the queen bee. Because of its pleiotropic functions for queen bees, RJ has also been used as a dietary supplement with various health benefits for humans. Because RJ is being indicated to have immunomodulatory potential for humans, we undertook the study to determine whether the oral administration of RJ could alter the development of systemic autoimmunity in New Zealand Black (NZB) x New Zealand White (NZW) F1 mice that genetically exhibit many manifestations similar to human systemic lupus erythematosus (SLE). We herein reported that mice administered with RJ showed a significant delay in the onset of the disease, as manifested by decreased proteinuria and a prolongation of lifespan. In addition, RJ administration after the onset of the disease significantly improved the renal symptoms, leading to an extended lifespan. RJ administration to mice caused a significant decrease in the serum level of IL-10, and in the autoantibodies against ssDNA, dsDNA and erythrocytes, as well as a reduction in the number of splenic autoreactive B cells. In conclusion, our data suggest that the use of RJ may be beneficial in the prevention of the early onset of SLE and in the control of the active progression of the manifestations of SLE.

Key Words: autoantibodies • autoreactive B cells • NZBx NZW F1 mice • royal jelly • systemic lupus erythematosus

Lupus, Vol. 18, No. 1, 44-52 (2009)
DOI: 10.1177/0961203308094765


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?